Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

Sikander Ailawadhi, Kirtipal Bhatia, Sonikpreet Aulakh, Zahara Meghji, Asher Chanan-Khan

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics. Research in multiple myeloma has specifically looked at several such patient subgroups based on socioeconomic status, age, race/ethnicity, insurance carrier, and geographic location that may affect healthcare utilization and patient outcomes. Exploring and understanding these would certainly help address disparities and lead to further equity in healthcare access and, hopefully, patient outcomes.

Original languageEnglish (US)
Pages (from-to)309-316
Number of pages8
JournalCurrent Hematologic Malignancy Reports
Issue number4
StatePublished - Aug 1 2017


  • Disparity
  • Myeloma
  • Outcomes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?'. Together they form a unique fingerprint.

Cite this